– CANADA, Vancouver – Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Mark Corrigan, M.D. to its board of directors, effective immediately. Dr. Corrigan will serve as a member of the compliance committee.
Jason Aryeh, chairman of the board of directors, said, “As a highly successful industry executive and board member, we believe Dr. Corrigan will be a strong contributor to the strategic direction of Novelion, particularly as we seek to maximize the value of metreleptin by expanding the pipeline of indications in development. In addition, we believe Dr. Corrigan’s complementary scientific expertise and strong strategic track record will augment the new Board’s focus on maximizing shareholder value with proper compliance and strong corporate governance.”
Dr. Corrigan was previously president and chief executive officer of Zalicus Inc. Prior to that, he was executive vice president, research & development of Sepracor Inc. (now Sunovion Pharmaceuticals). Prior to joining Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn, Inc., most recently as group vice president of global clinical research and experimental medicine. Dr. Corrigan currently serves on the board of directors of Cardiome Pharma Corp. (NASDAQ:CRME) and on the supervisory board of Nabriva Therapeutics AG (NASDAQ:NBRV). He previously served as a director of CoLucid Pharmaceuticals, Inc., Avanir Pharmaceuticals, Inc., EPIRUS Biopharmaceuticals, Inc. and Cubist Pharmaceuticals, Inc. He was chairman of the board of EPIRUS and served on the audit committee and nominating and governance committee and chaired the scientific affairs committee of Cubist’s board.
Dr. Corrigan spent five years in academic research at the University of North Carolina Medical School, focusing on psychoneuroendocrinology. Dr. Corrigan holds a B.A. and an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.
The company also announced that effective immediately, Sandford Smith will step down from the Novelion Board of Directors.
“We thank Sandy for serving as vice chairman, and for his shared vision towards the creation of Novelion Therapeutics,” continued Mr. Aryeh.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT and JUXTAPID, and is also developing zuretinol acetate for the potential treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
For more information : http://www.novelion.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.